AstraZeneca Investor Day Presentation Deck

ORR in patients with measurable disease 10% improvement in ORR with olaparib + abiraterone Rate (%) 70 60 50 40 30 20 10 0 T ORR 58.4% 54.0% PR 4.3% CR OR 1.60 (95% CI 1.02-2.53) P=0.0409* SD 26.1% PD 13.7% Olaparib + abiraterone (n=161) ORR 48.1% 41.9% PR 6.3% CR SD 28.1% PD 19.4% Placebo + abiraterone (n=160) 33 *Nominal. CR = complete response; OR = odds ratio; ORR = overall response rate; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease. 321/796 patients (40.3%) had measurable disease by RECIST v1.1 criteria at baseline B

View entire presentation